Long-Lived Positron Emitters Zirconium-89 and Iodine-124 for Scouting of Therapeutic Radioimmunoconjugates with PET
- 1 August 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 18 (4) , 655-661
- https://doi.org/10.1089/108497803322287745
Abstract
Antibody-PET imaging might be of value for the selection of radioimmunotherapy (RIT) candidates to confirm tumor targeting and to estimate radiation doses to tumor and normal tissues. One of the requirements to be set for such a scouting procedure is that the biodistributions of the diagnostic and therapeutic radioimmunoconjugates should be similar. In the present study we evaluated the potential of the positron emitters zirconium-89 (89Zr) and iodine-124 (124I) for this approach, as these radionuclides have a relatively long half-life that matches with the kinetics of MAbs in vivo (t1/2 3.27 and 4.18 days, respectively). After radiolabeling of the head and neck squamous cell carcinoma (HNSCC)-selective chimeric antibody (cMAb) U36, the biodistribution of two diagnostic (cMAb U36-N-sucDf-89Zr and cMAb U36-124I) and three therapeutic radioimmunoconjugates (cMAb U36-p-SCN-Bz-DOTA-88Y-with 88Y being substitute for 90Y, cMAb U36-131I, and cMAb U36-MAG3-186Re) was assessed in mice with HNSCC-xenografts, at 24, 48, and 72 hours after injection. Two patterns of biodistribution were observed, one pattern matching for 89Zr- and 88Y-labeled cMAb U36 and one pattern matching for 124I-, 131I-, and 186Re-cMAb U36. The most remarkable differences between both patterns were observed for uptake in tumor and liver. Tumor uptake levels were 23.2 ± 0.5 and 24.1 ± 0.7%ID/g for the 89Zr- and 88Y-cMAb U36 and 16.0 ± 0.8, 15.7 ± 0.79 and 17.1 ± 1.6%ID/g for 124I-, 131I-, and 186Re-cMAb U36-conjugates, respectively, at 72 hours after injection. For liver these values were 6.9 ± 0.8 (89Zr), 6.2 ± 0.8 (88Y), 1.7 ± 0.1 (124I), 1.6 ± 0.1 (131I), and 2.3 ± 0.1 (186Re), respectively. These preliminary data justify the further development of antibody-PET with 89Zr-labeled MAbs for scouting of therapeutic doses of 90Y-labeled MAbs. In such approach 124I-labeled MAbs are most suitable for scouting of 131I- and 186Re-labeled MAbs.Keywords
This publication has 9 references indexed in Scilit:
- Role of radiation dosimetry in radioimmunotherapy planning and treatment dosingCritical Reviews in Oncology/Hematology, 2001
- High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragmentProceedings of the National Academy of Sciences, 2000
- Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- A new era for radiolabeled antibodies in cancer?Current Opinion in Immunology, 1999
- Tumor Retention of 186Re-MAG3, 111In-DTPA and 125I Labeled Monoclonal Antibody G250 in Nude Mice with Renal Cell Carcinoma XenograftsCancer Biotherapy & Radiopharmaceuticals, 1998
- Comparison of the biodistribution and the efficacy of monoclonal antibody labeled with either 131I or 186Re in human ovarian cancer xenograftsInternational Journal of Radiation Oncology*Biology*Physics, 1997
- An investigation of the physical characteristics of 66Ga as an isotope for PET imaging and quantificationMedical Physics, 1997
- Production and purification of 89Zr, a potential PET antibody labelInternational Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 1990
- Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excessJournal of Immunological Methods, 1984